Clinical records | Before PSM | After PSM | ||||||
---|---|---|---|---|---|---|---|---|
Uniportal cohort (n = 35) | Three-port cohort (n = 317) | Z/X2-value | p-value | Uniportal cohort (n = 33) | Three-port cohort (n = 33) | Z/X2-value | p-value | |
Age (years) | 78(76, 79) | 77(76, 79) | —1.00 | 0.32 | 77(76, 79) | 77(76, 78) | —0.70 | 0.48 |
Sex | 4.50 | 0.03 | 0.24 | 0.62 | ||||
Male | 16(45.70%) | 203(64.00%) | 16(48.50%) | 14(42.40%) | ||||
Female | 19(54.30%) | 114(36.00%) | 17(51.50%) | 19(57.60%) | ||||
Smoking history | 0.001 | 0.98 | < 0.0001 | > 0.99 | ||||
Yes | 15(42.90%) | 135(42.60%) | 15(45.50%) | 15(45.50%) | ||||
No | 20(57.10%) | 182(57.40%) | 18(54.50%) | 18(54.50%) | ||||
Comorbidity | 23(65.70%) | 223(70.30%) | 0.32 | 0.57 | 21(63.60%) | 20(60.60%) | 0.06 | 0.80 |
Diabetes mellitus | 5(14.30%) | 48(15.10%) | 0.02 | 0.89 | 5(15.20%) | 3(9.10%) | 0.57 | 0.45 |
Hypertension | 16(45.70%) | 137(43.20%) | 0.08 | 0.78 | 14(42.40%) | 14(42.40%) | < 0.0001 | > 0.99 |
COPD | 2(5.70%) | 38(12.00%) | 0.69 | 0.41 | 2(6.10%) | 1(3.00%) | 0.35 | 0.56 |
CHD | 7(20.00%) | 41(12.90%) | 0.80 | 0.37 | 5(15.20%) | 5(15.20%) | < 0.0001 | > 0.99 |
History of other cancer | 3(8.60%) | 23(7.30%) | < 0.0001 | > 0.99 | 3(9.10%) | 1(3.00%) | 0.27 | 0.61 |
FEV1% | 99.90(86.90, 114.40) | 103.67(89.75, 111.85) | —0.40 | 0.69 | 103.67(89.80, 116.05) | 103.67(90.85, 125.60) | —0.62 | 0.53 |
FVC% | 105.70(91.10, 122.80) | 109.57(96.85, 117.45) | —0.54 | 0.59 | 106.60(96.95, 124.10) | 108.90(97.45, 126.35) | —0.41 | 0.68 |
Degree of fissure development | 1.70 | 0.43 | —0.71 | 0.48 | ||||
No developemnt | 1(2.90%) | 8(2.50%) | 1(3.00%) | 1(3.00%) | ||||
Incomplete development | 18(51.40%) | 199(62.80%) | 17(51.50%) | 20(60.60%) | ||||
Well development | 16(45.70%) | 110(34.70%) | 15(45.50%) | 12(36.40%) | ||||
Degree of pleural adhesion | 0.47 | 0.50 | 1.22 | 0.27 | ||||
Have adhesion | 28(80.00%) | 237(74.80%) | 26(78.80%) | 22(66.70%) | ||||
No adhesion | 7(20.00%) | 80(25.20%) | 7(21.20%) | 11(33.30%) | ||||
Tumor size (cm) | 2.40(1.80, 3.20) | 2.70(2.00, 3.80) | —1.41 | 0.16 | 2.40(1.80, 3.35) | 2.30(1.95, 2.75) | —0.67 | 0.50 |
TNM stage | —1.45 | 0.15 | —0.90 | 0.37 | ||||
IA | 21(60.00%) | 161(50.80%) | 19(57.60%) | 23(69.70%) | ||||
IB | 7(20.00%) | 52(16.40%) | 7(21.20%) | 4(12.10%) | ||||
IIA | 4(11.40%) | 25(7.90%) | 4(12.10%) | 3(9.10%) | ||||
IIB | 0(0.00%) | 30(9.50%) | 0(0.00%) | 1(3.00%) | ||||
IIIA | 2(5.70%) | 36(11.40%) | 2(6.10%) | 2(6.10%) | ||||
IIIB | 1(2.90%) | 13(4.10%) | 1(3.00%) | 0(0.00%) | ||||
Complete resection | – | > 0.99 | – | – | ||||
Yes | 35(100.00%) | 315(99.40%) | 33(100.00%) | 33(100.00%) | ||||
No | 0(0.00%) | 2(0.60%) | 0(0.00%) | 0(0.00%) |